• linkedin
  • Increase Font
  • Sharebar

    Rheumatologic side effects possible with immunotherapies


    In a press release from Johns Hopkins, Dr. Cappelli said she wants the findings to raise awareness that rheumatologic side effects may occur with these drugs.

    Read: Immunotherapy approved for advanced urothelial Ca

    “It is important when weighing the risk-benefit ratio of prescribing these drugs. And it’s important for people to be on the lookout for symptoms so they can see a rheumatologist early in an effort to prevent or limit joint damage,” Dr. Cappelli said.

    Dr. Ramin noted that there have been developments in new immunotherapy drugs for bladder and kidney cancer, and so understanding the side effects are important for these agents, as well.

    The current study did not examine patients receiving atezolizumab (Tecentriq). It did, however, include patients receiving nivolumab, which received FDA approval in November 2015 for the treatment of patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. Earlier this month, nivolumab was granted FDA approval for treatment of patients with previously treated locally advanced or metastatic urothelial carcinoma. The second drug in the study, ipilimumab, is indicated for the treatment of unresectable or metastatic melanoma.

    Immunotherapy is increasingly identified as the best option for a growing number of cancers, many of which were previously intractable. That’s why the American Society of Clinical Oncology and the National Comprehensive Cancer Network are collaborating on practical clinical guidance for the management of side effects caused by immunotherapy.

    While these side effects are generally mild and infrequent, when they do occur, they can be serious and even life threatening if not identified and treated in a timely manner.

    “It is very conceivable that as the immune system becomes highly activated to attack foreign cells, it may also attack some native cells, especially in the joints,” Dr. Ramin said. “In the future, we will see higher levels of specificity in tailor-made drugs for patients’ malignancies. As our treatments become more targeted, the level of efficacy will increase, while the intensity of side effects will diminish.”

    Several of Dr. Cappelli’s co-authors have a financial and/or other relationship with Bristol-Myers Squibb and/or other pharmaceutical companies.

    More on Bladder Cancer:

    Bladder Ca guide provides risk-stratified framework

    Bladder cancer surveillance: Challenges and opportunities

    Study data may help risk stratify microhematuria Dx

    To get weekly news from the leading news source for urologists, subscribe to the Urology Times eNews.

    Keith Loria
    Keith Loria is a contributing writer to Medical Economics.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results